MedTrace Logo

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

NCT07011589 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-05-05

No results posted yet for this study

Summary

The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum.

Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.

Conditions

Interventions

BIOLOGICAL

Efgartigimod

Dosage: 10mg/kg Frequency: Once a week Duration: 25 weeks

Sponsors & Collaborators

  • argenx

    collaborator INDUSTRY

  • M. Peter Marinkovich

    lead OTHER

Principal Investigators

  • Matt P Marinkovich, MD · Associate Professor of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07011589 on ClinicalTrials.gov